Abstract: ObjectiveTo analyze the risk of tocilizumab when used in China in order to provide reference for clinical rational drug use. Methods The individual adverse drug reaction cases reported by WHO Vigilyze and China adverse drug reaction database, domestic literature and risk management plans of foreign regulatory agencies were analyzed. Results The risk of hepatic dysfunction, cutaneous damage, anaphylactic reaction, gastrointestinal disorders, infection and hematological damage should be guarded against. Conclusion We should reinforce the safety monitoring of tocilizumab by focusing on such adverse reactions as serious infections and liver damage, and promote the rational application of this medicine.

Key words: novel coronavirus pneumonia, immunoregulation, tocilizumab, adverse reaction